Yaqrit prepares phase 3 for ammonia scavenger in hepatic encephalopathy

Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designationsIV formulation to enter phase 3 in 2025; oral formulation to enter phase 2b trials for HE prevention and phase 2a for urea cycle disorders LONDON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver disease, annou ...